Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 18.91B | 11.25B | 13.80B | 11.57B | 9.80B |
Gross Profit | 8.01B | 4.09B | 5.58B | 4.84B | 4.38B |
EBITDA | 6.63B | 4.61B | 7.42B | 6.35B | 5.17B |
Net Income | 4.96B | 2.47B | 4.83B | 4.10B | 3.38B |
Balance Sheet | |||||
Total Assets | 36.94B | 31.86B | 32.12B | 28.29B | 19.87B |
Cash, Cash Equivalents and Short-Term Investments | 9.44B | 10.50B | 11.14B | 8.03B | 1.70B |
Total Debt | 1.78B | 2.40B | 3.24B | 4.28B | 5.05B |
Total Liabilities | 5.36B | 4.29B | 6.24B | 6.97B | 7.27B |
Stockholders Equity | 31.59B | 27.57B | 25.88B | 21.32B | 12.60B |
Cash Flow | |||||
Free Cash Flow | 605.75M | 1.19B | 4.84B | 2.71B | -872.24M |
Operating Cash Flow | 3.68B | 2.97B | 6.39B | 3.64B | 2.09B |
Investing Cash Flow | -3.12B | -1.78B | -1.56B | -932.88M | -2.96B |
Financing Cash Flow | -1.62B | -1.86B | -1.70B | 3.59B | 948.34M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | ¥64.55B | 8.47 | 2.00% | 5.44% | 8.53% | ||
79 Outperform | ¥17.75B | 12.01 | 3.59% | 4.85% | 80.14% | ||
74 Outperform | ¥104.32B | 19.47 | 1.09% | 96.61% | 133.90% | ||
74 Outperform | ¥80.95B | 9.21 | 4.20% | 4.87% | 5.07% | ||
70 Neutral | ¥173.39B | 11.06 | 6.37% | 3.55% | 3.93% | 6.03% | |
66 Neutral | ¥59.64B | 9.59 | 4.63% | 3.21% | -2.40% |
Tri Chemical Laboratories Inc. reported significant financial growth for the three months ended April 30, 2025, with net sales doubling and operating profit increasing by 157.6% compared to the previous year. This financial performance indicates a strong market position and potential positive implications for stakeholders, as the company maintains a robust capital adequacy ratio of 80.7% and forecasts continued growth in the fiscal year ending January 31, 2026.
The most recent analyst rating on (JP:4369) stock is a Buy with a Yen5100.00 price target. To see the full list of analyst forecasts on Tri Chemical Laboratories Inc. stock, see the JP:4369 Stock Forecast page.
Tri Chemical Laboratories Inc. has signed a memorandum of understanding with Hefei ADChem Semi-Tech. Co., Ltd. to explore joint ventures in the Chinese semiconductor market. This collaboration aims to leverage ADChem’s technological capabilities and market presence in China, though it is expected to have minimal impact on Tri Chemical’s performance in the current fiscal year.
The most recent analyst rating on (JP:4369) stock is a Buy with a Yen5100.00 price target. To see the full list of analyst forecasts on Tri Chemical Laboratories Inc. stock, see the JP:4369 Stock Forecast page.
Tri Chemical Laboratories Inc. has completed the construction of a new plant in Minami-Alps City, Yamanashi Prefecture, aimed at manufacturing new etching and CVD materials for next-generation semiconductors. The plant, which represents an investment of approximately 12 billion yen, is expected to begin operations in the first half of 2025. This development is part of the company’s strategic expansion to enhance its production capabilities and market positioning in the semiconductor industry.